EdgarLookup

Rezolute, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Rezolute, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-42.4%
Return on Assets
Net income ÷ assets
0.08x
Debt-to-Equity
Total liabilities ÷ equity

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($74.41M) Sep 17, 2025
FY2025 Jun 30, 2024 ($68.46M) Sep 17, 2025
FY2024 Jun 30, 2023 ($51.79M) Sep 19, 2024
FY2023 Jun 30, 2022 ($41.06M) Sep 14, 2023
FY2022 Jun 30, 2021 ($20.90M) Sep 15, 2022
FY2021 Jun 30, 2020 ($20.33M) Sep 15, 2021
FY2020 Jun 30, 2019 ($30.45M) Oct 13, 2020
FY2019 Jun 30, 2018 ($29.86M) Sep 10, 2019
FY2018 Jun 30, 2017 ($20.28M) Oct 15, 2018
FY2017 Jun 30, 2016 ($14.94M) Sep 22, 2017

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($79.89M) Sep 17, 2025
FY2025 Jun 30, 2024 ($70.42M) Sep 17, 2025
FY2024 Jun 30, 2023 ($55.99M) Sep 19, 2024
FY2023 Jun 30, 2022 ($41.84M) Sep 14, 2023
FY2022 Jun 30, 2021 ($22.89M) Sep 15, 2022
FY2021 Jun 30, 2020 ($20.52M) Sep 15, 2021
FY2020 Jun 30, 2019 ($25.94M) Oct 13, 2020
FY2019 Jun 30, 2018 ($28.73M) Sep 10, 2019
FY2018 Jun 30, 2017 ($20.32M) Oct 15, 2018
FY2017 Jun 30, 2016 ($14.95M) Sep 22, 2017

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $61.53M Sep 17, 2025
FY2025 Jun 30, 2024 $55.74M Sep 17, 2025
FY2024 Jun 30, 2023 $43.81M Sep 19, 2024
FY2023 Jun 30, 2022 $32.49M Sep 14, 2023
FY2022 Jun 30, 2021 $14.99M Sep 15, 2022
FY2021 Jun 30, 2020 $14.45M Sep 15, 2021
FY2020 Jun 30, 2019 $19.08M Oct 13, 2020
FY2019 Jun 30, 2018 $17.28M Sep 10, 2019
FY2018 Jun 30, 2017 $12.09M Oct 15, 2018
FY2017 Jun 30, 2016 $9.45M Sep 22, 2017

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($69.08M) Sep 17, 2025
FY2025 Jun 30, 2024 ($57.37M) Sep 17, 2025
FY2024 Jun 30, 2023 ($44.48M) Sep 19, 2024
FY2023 Jun 30, 2022 ($39.62M) Sep 14, 2023
FY2022 Jun 30, 2021 ($20.44M) Sep 15, 2022
FY2021 Jun 30, 2020 ($24.17M) Sep 15, 2021
FY2020 Jun 30, 2019 ($15.30M) Oct 13, 2020
FY2019 Jun 30, 2018 ($14.11M) Sep 10, 2019
FY2018 Jun 30, 2017 ($13.31M) Oct 15, 2018
FY2013 Jun 30, 2013 ($1.63M) Sep 11, 2013

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2024 Jun 30, 2023 $153.0K Sep 19, 2024
FY2020 Jun 30, 2020 $0 Oct 13, 2020
FY2020 Jun 30, 2019 $47.0K Oct 13, 2020
FY2019 Jun 30, 2018 $6.0K Sep 10, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $175.49M Sep 17, 2025
FY2025 Jun 30, 2024 $132.74M Sep 17, 2025
FY2024 Jun 30, 2023 $123.72M Sep 19, 2024
FY2023 Jun 30, 2022 $152.42M Sep 14, 2023
FY2022 Jun 30, 2021 $42.61M Sep 15, 2022
FY2021 Jun 30, 2020 $10.97M Sep 15, 2021
FY2020 Jun 30, 2019 $12.25M Oct 13, 2020
FY2019 Jun 30, 2018 $2.50M Sep 10, 2019
FY2018 Jun 30, 2017 $10.63M Oct 15, 2018
FY2017 Jun 30, 2016 $10.90M Sep 22, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $13.36M Sep 17, 2025
FY2025 Jun 30, 2024 $11.73M Sep 17, 2025
FY2024 Jun 30, 2023 $7.55M Sep 19, 2024
FY2023 Jun 30, 2022 $2.95M Sep 14, 2023
FY2022 Jun 30, 2021 $16.51M Sep 15, 2022
FY2021 Jun 30, 2020 $3.60M Sep 15, 2021
FY2020 Jun 30, 2019 $10.50M Oct 13, 2020
FY2019 Jun 30, 2018 $6.46M Sep 10, 2019
FY2018 Jun 30, 2017 $2.10M Oct 15, 2018
FY2017 Jun 30, 2016 $2.13M Sep 22, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $162.13M Sep 17, 2025
FY2025 Jun 30, 2024 $121.00M Sep 17, 2025
FY2025 Jun 30, 2023 $116.17M Sep 17, 2025
FY2024 Jun 30, 2022 $149.47M Sep 19, 2024
FY2023 Jun 30, 2021 $26.10M Sep 14, 2023
FY2022 Jun 30, 2020 $7.37M Sep 15, 2022
FY2021 Jun 30, 2019 $1.75M Sep 15, 2021
FY2020 Jun 30, 2018 ($3.96M) Oct 13, 2020
FY2019 Jun 30, 2017 $8.53M Sep 10, 2019
FY2018 Jun 30, 2016 $8.77M Oct 15, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($403.86M) Sep 17, 2025
FY2025 Jun 30, 2024 ($329.44M) Sep 17, 2025
FY2024 Jun 30, 2023 ($260.99M) Sep 19, 2024
FY2023 Jun 30, 2022 ($209.20M) Sep 14, 2023
FY2022 Jun 30, 2021 ($168.14M) Sep 15, 2022
FY2021 Jun 30, 2020 ($147.24M) Sep 15, 2021
FY2020 Jun 30, 2019 ($126.90M) Oct 13, 2020
FY2019 Jun 30, 2018 ($94.18M) Sep 10, 2019
FY2018 Jun 30, 2017 ($64.32M) Oct 15, 2018
FY2017 Jun 30, 2016 ($44.04M) Sep 22, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $94.11M Sep 17, 2025
FY2025 Jun 30, 2024 $70.40M Sep 17, 2025
FY2024 Jun 30, 2023 $16.04M Sep 19, 2024
FY2023 Jun 30, 2022 $150.41M Sep 14, 2023
FY2022 Jun 30, 2021 $41.05M Sep 15, 2022
FY2021 Jun 30, 2020 $9.96M Sep 15, 2021
FY2020 Jun 30, 2019 $11.57M Oct 13, 2020
FY2019 Jun 30, 2018 $1.65M Sep 10, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2022 Jun 30, 2021 $13.97M Sep 15, 2022
FY2021 Jun 30, 2020 $0 Sep 15, 2021
FY2019 Jun 30, 2019 $0 Sep 10, 2019
FY2019 Jun 30, 2018 $3.43M Sep 10, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Sep 17, 2025
FY2025 Jun 30, 2024 (1) Sep 17, 2025
FY2024 Jun 30, 2023 (1) Sep 19, 2024
FY2023 Jun 30, 2022 (2) Sep 14, 2023
FY2022 Jun 30, 2021 (2) Sep 15, 2022
FY2014 Jun 30, 2014 (1) Sep 30, 2014
FY2014 Jun 30, 2013 (1) Sep 30, 2014
FY2013 Jun 30, 2012 0 Sep 11, 2013
FY2013 Dec 31, 2011 0 Sep 11, 2013

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Sep 17, 2025
FY2025 Jun 30, 2024 (1) Sep 17, 2025
FY2024 Jun 30, 2023 (1) Sep 19, 2024
FY2023 Jun 30, 2022 (2) Sep 14, 2023
FY2022 Jun 30, 2021 (2) Sep 15, 2022
FY2014 Jun 30, 2014 (1) Sep 30, 2014
FY2014 Jun 30, 2013 (1) Sep 30, 2014
FY2013 Jun 30, 2012 0 Sep 11, 2013
FY2013 Dec 31, 2011 0 Sep 11, 2013

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 87.00M Sep 17, 2025
FY2025 Jun 30, 2024 53.25M Sep 17, 2025
FY2024 Jun 30, 2023 36.83M Sep 19, 2024
FY2023 Jun 30, 2022 33.58M Sep 14, 2023
FY2022 Jun 30, 2021 8.35M Sep 15, 2022
FY2022 Feb 17, 2021 8.40M Sep 15, 2022
FY2021 Jun 30, 2020 5.87M Sep 15, 2021
FY2022 Aug 31, 2019 1 Sep 15, 2022
FY2020 Jun 30, 2019 4.21M Oct 13, 2020
FY2019 Jun 30, 2018 62,166 Sep 10, 2019